To compare subsequent cardiovascular risks, including heart failure, myocardial infarction, angina pectoris, stroke, and atrial fibrillation, following the use of different SGLT2 inhibitors, Suzuki et al. analyzed a large-scale real-world dataset comprising approximately 25,000 patients with diabetes mellitus who were newly prescribed SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ipragliflozin, tofogliflozin, and luseogliflozin) in Japan. The gene discussed is SLC5A2; the disease is diabetes mellitus.